Imagion Biosystems logo

Imagion Biosystems(ASX) IBX

Market CapA$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-83%
1 Month-25%
A$0.01
-14.29%
-0.00Today
Imagion Biosystems last closing stock price
MetricPriceDate
Last closeAUD 0.012026-10-07
Imagion Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.29%AUD 0.012026-09-30
1 month-25%AUD 0.012026-09-07
3 month-50%AUD 0.012026-07-09
Year to date-76%AUD 0.032025-12-31
1 year-82.86%AUD 0.042025-10-07
3 year-99.12%AUD 0.682023-10-06
5 year-99.8%AUD 2.962021-10-08
Since inception-99.89%AUD 5.362017-06-22

Imagion Biosystems Financials at a Glance

Market Cap

A$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.06M

Net Income (TTM)

-A$6.83M

EPS (TTM)

-A$0.01

P/E Ratio

-0.53

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Price

A$0.01

Volume

0

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.04

Estimated Earnings Date

Feb 26, 2026

IBX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imagion Biosystems

Imagion Biosystems Limited is a medical imaging company focused on developing innovative technologies for cancer detection. Utilizing bio-safe magnetic nanoparticles, the company aims to enhance diagnostic capabilities in oncology and other diseases.

Products and Services
  • MagSense, a Phase 2 imaging agent for HER2 breast cancers
  • PrecisionMRX, an iron oxide nanoparticle for magnetic relaxometry
  • Collaboration with Wayne State University for optimized MRI sequences
Growth Outlook
  • Advancements in MagSense could lead to significant market opportunities
  • Ongoing research in prostate and ovarian cancer diagnostics
  • Potential for partnerships to expand product offerings and reach
Financial Highlights
  • Recent quarterly net income of -$1.98 million, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) revenue of $0, indicating early-stage development
  • Cash and cash equivalents of $32,456 as of June 30, 2026
Imagion Biosystems Limited operates in the healthcare sector, specifically within medical diagnostics and research. The company is dedicated to advancing cancer detection technologies through its proprietary nanoparticle-based imaging solutions. With a focus on innovative research and development, Imagion aims to address significant unmet needs in cancer diagnostics, particularly in breast, prostate, and ovarian cancers. The collaboration with Wayne State University highlights the commitment to enhancing imaging techniques, which may lead to improved patient outcomes. Despite current financial challenges, including a recent quarterly net loss, the potential for future growth remains strong as the company continues to develop its product pipeline and explore strategic partnerships.
AI Generated • Sep 23, 2026

Industry

Healthcare Equipment and Supplies

CEO

Isaac J. Bright, MD, MBA

Headquarters

Melbourne, VIC 3000, AU

IBX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

165.88%

Return on Capital

-890.72%

Return on Assets

-688.94%

Earnings Yield

-1.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

801.01M

Volume

0

Avg. Volume

1.84M

Financials (TTM)

Gross Profit

A$369.67K

Operating Income

-A$6.32M

EBITDA

-A$5.63M

Operating Cash Flow

-A$6.94M

Capital Expenditure

A$3.00

Free Cash Flow

-A$6.94M

Cash & ST Invst.

A$32.46K

Total Debt

A$2.19M

Imagion Biosystems Performance Analysis

Imagion Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 473,429103.3%
20232023-12-31AUD 1,082,937128.7%
20242024-12-31AUD 1,160,2117.1%
20252025-12-31AUD 0N/A
Imagion Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-37.0%
Q22025-06-30-97.5%
Q42025-12-31-100.0%
Q22026-06-30N/A
Imagion Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.3552.2%
20232023-12-31AUD -0.4116.9%
20242024-12-31AUD -0.05-88.8%
20252025-12-31AUD -0.02-66.3%
Imagion Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3179.9%
Q22025-06-3011.7%
Q42025-12-3112.0%
Q22026-06-3045.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$2.00K

-100.2%

Gross Margin

0.00%

N/A

Market Cap

A$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$436.91K

N/A

Employees

11

N/A

Net Income

-A$1.98M

-29.8%

EBITDA

-A$2.27M

-321.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$32.46K

-91.5%

Total Debt

A$2.19M

-31.3%

Accounts Receivable

A$565.72K

+61660.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$2.19M

-31.2%

Return on Assets

-6.89%

N/A

Return on Invested Capital

1.37%

N/A

Free Cash Flow

-A$1.79M

-1038.1%

Operating Cash Flow

-A$1.79M

-1038.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HIQ.AXHITIQ Limited
A$0.01+0.00%
IVX.AXInvion Limited
A$0.04-5.00%
GLH.AXGlobal Health Limited
A$0.06+0.00%
BIT.AXBiotron Limited
A$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.19-9.79%
WFFWf
$7.31+256.54%
VEEAVeea
$5.72+47.80%
SPCXSpace Exploration Technologies
$161.67+0.68%

Questions About IBX

What is the current price of Imagion Biosystems?

Imagion Biosystems is trading at A$0.01 per share.

What is the 52-week range for Imagion Biosystems?

Over the past 52 weeks, Imagion Biosystems has traded between A$0.01 and A$0.04.

How much debt does Imagion Biosystems have?

As of the most recent reporting period, Imagion Biosystems reported total debt of A$2.56M.

How much cash does Imagion Biosystems have on hand?

Imagion Biosystems reported A$1.85M in cash and cash equivalents in its most recent financial results.

What is Imagion Biosystems’s dividend yield?

Imagion Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.